Fireside Chat: Shaping the Future of Cell & Gene Therapy Access

• Examining how evolving clinical data, payer expectations and policy shifts are redefining commercial success for advanced therapies
• Understanding how affordability pressures, evidence requirements and real-world delivery constraints are shaping near term and long-term market viability
• Exploring what manufacturers, payers and providers need to prioritize to sustain patient access as pipelines expand into larger and more common indications

Speakers:

Kimberly Burlison

Head of US Market Access

Orchard Therapeutics

Laura Okpala

Executive Director & Head of Reimbursement Policy & Government Affairs

Gilead Sciences

Mark Trusheim

Senior Strategy Advisor, NEWDIGS

Tufts Medical Center